Luke Timmerman

Luke Timmerman's Everest Base Camp Trek

Curing cancer one mountain at a time.

Luke Timmerman and Team Everest Base Camp seek to raise $1 million for cancer research at Fred Hutch.

Hike Amid Himalayan Giants With Biotech Leaders

Following a successful summit of Mt. Everest in 2018 and an extraordinary inaugural team summit of Mt. Kilimanjaro in 2019, Luke Timmerman has set his sights on a new adventure: hiking the Himalayas’ storied trails to Everest Base Camp. Executives and investors from the biotech and pharmaceutical industries will come together to form Team Everest Base Camp and will travel to Nepal in March 2020.

Each Team Everest Base Camp climber will raise $50,000 or more to support cancer research at Fred Hutch.

To make a donation, click here. If you would rather mail in a donation, please send your gift to the address below. Be sure to include the name of the climber you are donating to. For stock donations or bank transfer instructions, please email

Fred Hutch
ATTN: Climb to Fight Cancer
1100 Fairview Ave. N., Mail Stop J5-200
Seattle, WA 98109

Meet the Team

  • Luke Timmerman, founder and editor, Timmerman Report (team captain)
  • Doug Williams, president and CEO, Codiak Biosciences
  • Nathaniel David, co-founder and president, Unity Biotechnology; venture partner, ARCH Venture Parters
  • Nimesh Shah, managing director, Hercules Capital
  • Denise Aronson, founder and CEO, Safety Partners
  • Niki Robinson, vice president of business development and strategy, Fred Hutch
  • Bryce Robinson, MD, board-certified trauma surgeon. Associate medical director for Critical Care at Harborview Medical Center; associate professor of surgery, University of Washington
  • Jennifer Adair, assistant member, Clinical Research, Fred Hutch
  • Uciane Scarlett, venture investor 
  • Kent Hawryluk, chief business officer, Avidity Biosciences
  • Victor Clavelli, president of North America Inflammation & Immunology, Pfizer
  • Lewis T. "Rusty" Williams, physician, scientist, biotech entrepreneur
  • David Hoffman, executive director of IP, Parker Institue for Cancer Immunotherapy